Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence

Nature Communications

Volumn 6, Issue , 2015, Pages

  Sedic, Maja ^a,b   Skibinski, Adam ^a,b   Brown, Nelson ^b   Gallardo, Mercedes ^c   Mulligan, Peter ^d   Martinez, Paula ^c   Keller, Patricia J ^b   Glover, Eugene ^a,b   Richardson, Andrea L ^e   Cowan, Janet ^b   Toland, Amanda E ^f   Ravichandran, Krithika ^g   Riethman, Harold ^g   Naber, Stephen P ^b   Näär, Anders M ^d   Blasco, Maria A ^c   Hinds, Philip W ^b   Kuperwasser, Charlotte ^a,b  

^a TUFTS UNIVERSITY   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c Centro Nacional de Investigations Oncológicas   (Spain)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; ATR PROTEIN; BRCA1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P53; SIRTUIN 1; RETINOBLASTOMA PROTEIN; SIRT1 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ACETYLENE; CANCER; CELL ORGANELLE; EROSION; GENOMICS; HEALTH RISK; MOLECULAR ANALYSIS; MUTATION; SENESCENCE;

ACETYLATION; ARTICLE; BREAST CANCER; BREAST EPITHELIUM CELL; CANCER RISK; CELL AGING; CELL CYCLE ARREST; CELL PROLIFERATION; CHROMOSOME ABERRATION; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; ENZYME ACTIVATION; EPITHELIUM CELL; FEMALE; FIBROBLAST; GENE MUTATION; GENOMIC INSTABILITY; HAPLOINSUFFICIENCY; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MASTECTOMY; PHENOTYPE; PREMATURE CELL AGING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TELOMERE; TETRAPLOIDY; CYTOLOGY; GENETICS; HETEROZYGOTE; MAMMARY GLAND; METABOLISM; MUTATION; TELOMERE SHORTENING; TUMOR SUPPRESSOR GENE;

CELL AGING; DNA DAMAGE; EPITHELIAL CELLS; GENES, BRCA1; GENOMIC INSTABILITY; HAPLOINSUFFICIENCY; HETEROZYGOTE; HUMANS; MAMMARY GLANDS, HUMAN; MUTATION; RETINOBLASTOMA PROTEIN; SIRTUIN 1; TELOMERE SHORTENING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84934954473     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms8505     Document Type: Article

References (70)

1. Narod, S. A. & Foulkes, W. D. BRCA1 and BRCA2: 1994 and beyond. Nat. Rev. Cancer 4, 665-676 (2004).
2. Deng, C.-X. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res. 34, 1416-1426 (2006).
3. Komenaka, I. K. et al. The development of interval breast malignancies in patients with BRCA mutations. Cancer 100, 2079-2083 (2004).
4. Robson, M. et al. BRCA-associated breast cancer in young women. J. Clin. Oncol. 16, 1642-1649 (1998).
5. Campeau, P. M., Foulkes, W. D. & Tischkowitz, M. D. Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum. Genet. 124, 31-42 (2008).
6. Cao, L., Li, W., Kim, S., Brodie, S. G. & Deng, C. X. Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 fulllength isoform. Genes Dev. 17, 201-213 (2003).
7. Drost, R. M. & Jonkers, J. Preclinical mouse models for BRCA1-associated breast cancer. Br. J. Cancer 101, 1651-1657 (2009).
8. Zhang, J. & Powell, S. N. The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol. Cancer Res. 3, 531-539 (2005).
9. Huen, M. S. Y., Sy, S. M. H. & Chen, J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat. Rev. 11, 136-148 (2010).
10. Roy, R., Chun, J. & Powell, S. N. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat. Rev. 12, 68-78 (2012).
11. Musolino, A. et al. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study. Breast 16, 280-292 (2007).
12. Tlsty, T. D. A twist of cell fate. Cell Stem Cell 8, 126-127 (2011).
13. Whittemore, A. S., Gong, G. & Itnyre, J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am. J. Hum. Genet. 60, 496-504 (1997).
14. Clarke, C. L. et al. Mapping loss of heterozygosity in normal human breast cells from BRCA1/2 carriers. Br. J. Cancer 95, 515-519 (2006).
15. Martins, F. C. et al. Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov. 2, 503-511 (2012).
16. Lim, E. et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat. Med. 15, 907-913 (2009).
17. Proia, T. A. et al. Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell 8, 149-163 (2011).
18. Baldeyron, C. et al. A single mutated BRCA1 allele leads to impaired fidelity of double strand break end-joining. Oncogene 21, 1401-1410 (2002).
19. Rennstam, K. et al. Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency. Genes Chromosomes Cancer 49, 78-90 (2010).
20. Konishi, H. et al. Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc. Natl Acad. Sci. USA 108, 17773-17778 (2011).
21. Pathania, S. et al. BRCA1 haploinsufficiency for replication stress suppression in primary cells. Nat. Commun. 5, 5496 (2014).
22. Bakkenist, C. J., Drissi, R., Wu, J., Kastan, M. B. & Dome, J. S. Disappearance of the telomere dysfunction-induced stress response in fully senescent cells. Cancer Res. 64, 3748-3752 (2004).
23. Rappold, I., Iwabuchi, K., Date, T. & Chen, J. Tumor suppressor p53 binding protein 1 (53bp1) is involved in DNA damage-signaling pathways. J. Cell Biol. 153, 613-620 (2001).
24. Bellacosa, A. et al. Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations. Cancer Prev. Res. 3, 48-61 (2010).
25. Romanov, S. R. et al. Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. Nature 409, 633-637 (2001).
26. Soler, D., Genesca, A., Arnedo, G., Egozcue, J. & Tusell, L. Telomere dysfunction drives chromosomal instability in human mammary epithelial cells. Genes Chromosomes Cancer 44, 339-350 (2005).
27. Kannan, N. et al. The luminal progenitor compartment of the normal human mammary gland constitutes a unique site of telomere dysfunction. Stem Cell Rep. 1, 28-37 (2013).
28. Young, A. P. et al. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat. Cell Biol. 10, 361-369 (2008).
29. Kuilman, T., Michaloglou, C., Mooi, W. J. & Peeper, D. S. The essence of senescence. Genes Dev. 24, 2463-2479 (2010).
30. Berger, A. H., Knudson, A. G. & Pandolfi, P. P. A continuum model for tumour suppression. Nature 476, 163-169 (2011).
31. Hammond, S. L., Ham, R. G. & Stampfer, M. R. Serum-free growth of human mammary epithelial cells: rapid clonal growth in defined medium and extended serial passage with pituitary extract. Proc. Natl Acad. Sci. USA 81, 5435-5439 (1984).
32. Brenner, A. J., Stampfer, M. R. & Aldaz, C. M. Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation. Oncogene 17, 199-205 (1998).
33. Huschtscha, L. I. et al. Loss of p16INK4 expression by methylation is associated with lifespan extension of human mammary epithelial cells. Cancer Res. 58, 3508-3512 (1998).
34. Garbe, J. C. et al. Molecular distinctions between stasis and telomere attrition senescence barriers shown by long-term culture of normal human mammary epithelial cells. Cancer Res. 69, 7557-7568 (2009).
35. Garbe, J. C., Holst, C. R., Bassett, E., Tlsty, T. & Stampfer, M. R. Inactivation of p53 function in cultured human mammary epithelial cells turns the telomerelength dependent senescence barrier from agonescence into crisis. Cell Cycle 6, 1927-1936 (2007).
36. Coppe, J. P. et al. Senescence-associated secretory phenotypes reveal cellnonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 6, 2853-2868 (2008).
37. Rodier, F. et al. Persistent DNA damage signaling triggers senescenceassociated inflammatory cytokine secretion. Nat. Cell Biol. 11, 973-979 (2009).
38. Itahana, K., Dimri, G. & Campisi, J. Regulation of cellular senescence by p53. Eur. J. Biochem. 268, 2784-2791 (2001).
39. Wong, S. & Weber, J. D. Deacetylation of the retinoblastoma tumour suppressor protein by SIRT1. Biochem. J. 407, 451-460 (2007).
40. Langley, E. et al. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 21, 2383-2396 (2002).
41. Huang, J. et al. SIRT1 overexpression antagonizes cellular senescence with activated ERK/S6k1 signaling in human diploid fibroblasts. PLoS ONE 3, e1710 (2008).
42. Garcia-Cao, M., O'Sullivan, R., Peters, A. H., Jenuwein, T. & Blasco, M. A. Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases. Nat. Genet. 36, 94-99 (2004).
43. Dang, W. et al. Histone H4 lysine 16 acetylation regulates cellular lifespan. Nature 459, 802-807 (2009).
44. Wang, R. H. et al. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol. Cell 32, 11-20 (2008).
45. Tang, M. & Wong, A. S. T. Loss of BRCA1 regulates autophagy as a cellular stress response in breast and ovarian cancer cells. Cancer Res. 71, 3790 (2011).
46. Brown, N. E. et al. Cyclin D1 activity regulates autophagy and senescence in the mammary epithelium. Cancer Res. 72, 6477 (2012).
47. Salem, A. F., Howell, A., Sartini, M., Sotgia, F. & Lisanti, M. P. Downregulation of stromal BRCA1 drives breast cancer tumor growth via upregulation of HIF-1alpha, autophagy and ketone body production. Cell Cycle 11, 4167-4173 (2012).
48. Singh, K., Matsuyama, S., Drazba, J. & Almasan, A. Autophagy-dependent senescence in response to DNA damage and chronic apoptotic stress. Autophagy 8, 236-251 (2012).
49. Palacios, J. A. et al. SIRT1 contributes to telomere maintenance and augments global homologous recombination. J. Cell Biol. 191, 1299-1313 (2010).
50. Shay, J. W. & Wright, W. E. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis 26, 867-874 (2005).
51. Jonsson, G. et al. The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer. Cancer Res. 72, 4028-4036 (2012).
52. Hu, X. et al. Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol. Cancer Res. 7, 511-522 (2009).
53. Stefansson, O. A. et al. CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer. Epigenetics 6, 638-649 (2011).
54. Ginsburg, O. M. et al.Hereditary Breast Cancer Clinical Study Group. BRCA1 and BRCA2 families and the risk of skin cancer. Fam. Cancer 9, 489-493 (2010).
55. Xu, X. et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat. Genet. 22, 37-43 (1999).
56. Xu, X. et al. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell-cycle and tumorigenesis. Nat. Genet. 28, 266-271 (2001).
57. Bernards, R. et al. Structure and expression of the murine retinoblastoma gene and characterization of its encoded protein. Proc. Natl Acad. Sci. USA 86, 6474-6478 (1989).
58. Lane, T. F. et al. Expression of Brca1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice. Genes Dev. 9, 2712-2722 (1995).
59. Blasco, M. A. et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 91, 25-34 (1997).
60. Elenbaas, B. et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 15, 50-65 (2001).
61. Normand, J. & Karasek, M. A. A method for the isolation and serial propagation of keratinocytes, endothelial cells, and fibroblasts from a single punch biopsy of human skin. In. Vitro. Cell. Dev. Biol. Anim. 31, 447-455 (1995).
62. Miyoshi, H., Blomer, U., Takahashi, M., Gage, F. H. & Verma, I. M. Development of a self-inactivating lentivirus vector. J. Virol. 72, 8150-8157 (1998).
63. Shechter, D., Dormann, H. L., Allis, C. D. & Hake, S. B. Extraction, purification and analysis of histones. Nat. Protoc. 2, 1445-1457 (2007).
64. Debacq-Chainiaux, F., Erusalimsky, J. D., Campisi, J. & Toussaint, O. Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat. Protoc. 4, 1798-1806 (2009).
65. Lee, T. I., Johnstone, S. E. & Young, R. A. Chromatin immunoprecipitation and microarray-based analysis of protein location. Nat. Protoc. 1, 729-748 (2006).
66. Cawthon, R. M. Telomere measurement by quantitative PCR. Nucleic Acids Res. 30, e47 (2002).
67. Spearman, A. D. et al. Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance. J. Clin. Oncol. 26, 5393-5400 (2008).
68. Zijlmans, J. M. et al. Telomeres in the mouse have large inter-chromosomal variations in the number of T2AG3 repeats. Proc. Natl Acad. Sci. USA 94, 7423-7428 (1997).
69. Flores, I. et al. The longest telomeres: a general signature of adult stem cell compartments. Genes Dev. 22, 654-667 (2008).
70. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005).